Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK plc (GSK) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
03:35pm, Tuesday, 13'th Jun 2023
GSK plc (NYSE:GSK ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 12:20 PM ET Company Participants Tony Wood - Chief Scientific Officer Conference Call Participants Chris S
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
02:34pm, Wednesday, 07'th Jun 2023
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
June 2023 Stock Considerations
01:30am, Wednesday, 07'th Jun 2023
With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases. With the market still having a tough time in 2023 we see no shortages of stock
GSK's cancer drug Jemperli gets file acceptance from US FDA
02:59am, Tuesday, 06'th Jun 2023
GSK said on Tuesday that the U.S. Food and Drug Administration had granted file acceptance for its cancer drug, Jemperli, when combined with chemotherapy to treat adult patients with certain types of
Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating
04:57pm, Friday, 19'th May 2023
SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. Phase 3 MARIO trial data, pivotal for potential lab
What To Expect From GSK In 2023
01:29am, Tuesday, 16'th May 2023
GSK's operating income margin in Q1 2023 was 29.35%, showing an increase in the previous quarter and the last year. Vaccine sales were $2,493 million in Q1 2023, up 11.9% year-over-year, mainly due to
GSK: So, just how big is the RSV opportunity? Up to $9bn, says one broker
11:11am, Monday, 15'th May 2023
Shore Capital has examined the prospects of GSK PLC (LSE:GSK, NYSE:GSK)'s newly approved respiratory syncytial virus (RSV) vaccine, Arexvy, and believes it could eventually be a blockbuster several ti
3 Personalized Medicine Stocks to Buy for Long-Time Returns
07:50am, Monday, 15'th May 2023
Medicine is not always simple. A drug that cures one patient can easily kill another, based on anything from their weight to their genes to anything else.
GSK welcomes Zantac legal ruling in Canada
03:23am, Friday, 12'th May 2023
GSK PLC (LSE:GSK, NYSE:GSK) said it welcomed a legal ruling in Canada that saw a proposed class action made on behalf of users of a heartburn drug thrown out. The Brentford, UK-based pharmaceuticals
Dividend Portfolio Update: April 2023
11:00pm, Wednesday, 10'th May 2023
Markets continue to look shaky, real estate is starting to crack, precious metals doing pretty well but are still manipulated well below true value and the crypto world has started to thaw but nowhere
GSK's vaccine against RSV wins FDA approval
02:41pm, Thursday, 04'th May 2023
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's approval of GlaxoSmithKline's (GSK) vaccine against RSV.
FDA Approves First-Ever RSV Vaccine After Brutal 2022 Season
02:48pm, Wednesday, 03'rd May 2023
Decades after the first attempt was made, an RSV vaccine has finally been approved by the FDA.
FDA approves GSK RSV vaccine
01:56pm, Wednesday, 03'rd May 2023
The Food and Drug Administration on Wednesday approved GSK's GSK vaccine for respiratory syncytial virus (RSV), a highly contagious virus that causes lung and breathing-passage infections.
FDA approves GSK's RSV vaccine for older adults, world's first shot against virus
01:08pm, Wednesday, 03'rd May 2023
The FDA's approval is a victory for GSK in a race against Pfizer and Moderna to bring a shot that targets respiratory syncytial virus to the market.
GSK or TECH: Which Is the Better Value Stock Right Now?
12:56pm, Friday, 28'th Apr 2023
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both GSK (GSK) and Techne (TECH). But which of these two companies is the best option for those looking f
